A number of different tests can be used to check human immunodeficiency virus (HIV). These tests can be performed on blood samples or saliva samples. Blood samples can be obtained via an in-office finger prick or a blood draw in a laboratory. According to test type, the market is divided into three categories which includes screening, differentiation & confirmation test, and monitoring test. Antibody detection can be done using an enzyme-linked immunosorbent assay (ELISA) test, rapid test, and western blot test, in order to detect HIV infection. These tests are used as screening tests and/or confirmatory tests. HIV differentiation and confirmation tests are performed using western blot and immunofluorescence assay (IFA) methods. Monitoring testes includes CD4 count (is used to assess a patient’s immunologic response to antiretroviral treatment (ART) and Viral load tests (are used to quantify the amount of HIV-1 RNA circulating in the blood of an infected individual).
The global HIV diagnostics test market is estimated to be valued at US$ 4,263.62 million in 2022 and expected to reach US$ 8,487.17 million by 2030, witnessing a CAGR of 9.0% over the forecast period (2022-2030).
Figure 1. Global HIV Diagnostics Test Market Share (%), By Region, 2022
To learn more about this report, request a free sample copy
Rising government initiatives for increasing the number of HIV diagnostics test is expected to drive the growth of the global HIV diagnostics test market.
For instance, in 2020, Egypt government announced that it is offering free and confidential HIV diagnostics test at the examinations and counselling centers in all of the country’s 27 governorates.
Since the start of the COVID-19 pandemic, the Egypt government had been investing significantly to provide health services to all patients, especially those with chronic diseases including AIDS patients. Moreover, according to the Ministry of Health Saudi Arabia, the Ministry of Health (MoH) spent around US$ 71 billion in 2020 on healthcare awareness programs in Saudi Arabia.
According to a recent Gulf Cooperation Council (GCC) report published on June 27, 2021, Saudi Arabia plans to invest US$ 66.67 billion in healthcare infrastructure and boost private sector participation from 40% to 65% by 2030 in Saudi Arabia healthcare market.
HIV Diagnostics Test Market Report Coverage
|Market Size in 2022:
|US$ 4,263.62 Mn
|Historical Data for:
|2017 to 2020
|2022 to 2030
|Forecast Period 2022 to 2030 CAGR:
|2030 Value Projection:
|US$ 8,487.17 Mn
Abbott, Bio-Rad Laboratories, Inc., Hologic, Inc., Siemens Healthineers, Roche AG, Beckman Coulter Inc., OraSure Technologies, Inc., Becton, Dickinson and Company, Merck KGaA, Chembio Diagnostic Systems, Inc., Zyomyx Incorporation, Bristol –Myers Squibb, Janssen Pharmaceutica NV, QIAGEN N.V., and ViiV Healthcare Ltd.
|Restraints & Challenges:
Figure 2. Global HIV Diagnostics Test Market Share (%) Analysis, By Test Type, 2022
To learn more about this report, request a free sample copy
Increasing launch and development of technologically advanced HIV diagnostics test is expected to drive the growth of the global HIV diagnostics test market.
Key players operating in the market are focusing on the development and launch of technologically advanced HIV diagnostics test in order to expand their product portfolio and presence in the global market. For instance, in 2020, F. Hoffmann-La Roche AG, a Swiss multinational healthcare company, launched Elecsys HIV Duo immunoassay in the U.S., after it received approval from the U.S Food and Drug Administration (U.S. FDA) in April 2020. Elecsys HIV Duo is the first 4th generation HIV testing solution in the U.S. that allows separate detection of HIV p24 antigen and anti-HIV antibodies.
Moreover, in 2018, Abbott, a medical device and healthcare company, launched new point-of-care test called m-PIMA HIV-1/2 VL in The Netherlands. The test helps in the detection of HIV infection among the patients.
Global HIV Diagnostics Test Market – Impact of Coronavirus (COVID-19) Pandemic
Since the COVID-19 outbreak in December 2019, the disease has spread to over 100 countries across the globe. The coronavirus (COVID 19) pandemic and consequent lockdown in various countries across the globe have impacted the financial status of businesses in all sectors. Supply chain and manufacturing activities have been disrupted globally, due to lockdowns implemented by governments, restricted movement, and other COVID-19 safety precautions. Demand for HIV diagnostics test is expected to decrease during the pandemic.
According to a retrospective cohort study published by the John Wiley & Sons, Inc., in October 2021, using secondary data from the AIDS Healthcare Foundation (AHF) Global Quality Program from 44 countries in four continents (Asia, Latin America and the Caribbean, Europe and Africa), it was found that COVID-19 was associated with a significant reduction in HIV testing, an increase in the percentage of positive tests, a reduction in the number of in-person consultations and a reduction in the number of new enrolments in care, despite the implementation of several mitigation strategies. The impact of COVID-19 differed across continents and key populations.
Global HIV Diagnostics Test Market: Restraint
HIV stigmatization and inadequacy of HIV reagents & kits may act as a restraint for the growth of the global HIV diagnostics test market. For instance, according to Centers for Disease Control and Prevention (CDC), HIV stigma refers to irrational or negative attitudes, behavior, and judgments towards HIV-positive or HIV-infected people. It can have a negative impact on persons living with HIV's health and well-being by discouraging some people from knowing their HIV status, getting treatment, or staying in care.
Major players operating in the global HIV diagnostics test market include Abbott, Bio-Rad Laboratories, Inc., Hologic, Inc., Siemens Healthineers, Roche AG, Beckman Coulter Inc., OraSure Technologies, Inc., Becton, Dickinson and Company, Merck KGaA, Chembio Diagnostic Systems, Inc., Zyomyx Incorporation, Bristol –Myers Squibb, Janssen Pharmaceutica NV, QIAGEN N.V., and ViiV Healthcare Ltd.
Frequently Asked Questions